News ESC: Study says GLP-1s treat heart failure AND cut emissions Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.
News New heart attack data boost AZ’s Brilinta A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
